Abstract
Introduction: Patients with non-Hodgkin Lymphoma (NHL), especially adolescents and young adults, can face late effects from treatment, including decreased fertility. Due to time constraints prior to treatment initiation and sometimes financial limitations, implementing fertility counseling and referral-based guideline care remains challenging. We aim to understand the occurrence and predictors of fertility counseling and preservation in patients with NHL in the Lymphoma Epidemiology of Outcomes (LEO) cohort study.
Methods: The LEO cohort prospectively enrolled newly diagnosed patients with NHL from 2015-2020 at 8 academic medical centers in the US. Clinical. Treatment data were abstracted from medical records, pathology was reviewed and classified by a LEO pathologist, and participants completed a self-administered questionnaire. Participants were then prospectively followed to identify outcomes and collect additional patient reported data, including a survivorship questionnaire at follow-up 3 years (FU3) after diagnosis that included items on fertility counseling and preservation. The questionnaire contained two fertility questions analyzed: whether healthcare providers discussed the impact of lymphoma treatment on fertility, and whether providers discussed the process of fertility preservation.
This analysis was based on participants aged 18-50 years at enrollment and who completed the fertility questions at FU3. Women who had undergone natural or procedural menopause and men who had undergone vasectomy pre-treatment were excluded. We estimated the association of demographic and clinical factors with fertility preservation using odds ratios (ORs) and 95% confidence intervals (CI) from univariate and multivariable logistic regression models.
Results: Seventy-seven patients were included in the analysis: 36 females (46%) and 41 males (53%). The median age of diagnosis was 40 years (IQR 30-45), and 36 (47%) participants were in the age 18-39-year category. Participant self-identified race/ethnicity was 69% non-Hispanic White, 22% Hispanic, 4% Black and 3% Asian. Sixty (78%) patients were treated with alkylators, 12 (15.6%) with non-alkylators, and 5 (6.5%) with radiation. Fifty-five (71%) of the patients were classified as having aggressive lymphoma, with follicular, extranodal marginal zone, primary cutaneous follicle center, and nodal marginal zone B-cell lymphoma defined as indolent and remaining subtypes aggressive. Around 6% of female patients underwent fertility preservation after lymphoma diagnosis, compared to 12.2% of male patients. All the patients who had undergone fertility preservation after lymphoma diagnosis were in the 18-39-year age group.
On univariate analysis, females were more likely to have undergone fertility toxicity and preservation discussions compared to males, with 72% of females and 59% of males recalling a discussion regarding fertility (OR 1.8, 95% CI 0.7-4.9, p=0.21). Those age 18-39 were significantly more likely to have undergone fertility discussion compared to those aged 40-50 (OR 10.2, 95% CI 3.3-39.2, p<0.001). Patients treated with alkylating therapy were significantly more likely to undergo fertility discussion when compared to those on non-alkylating therapy (OR 9.0, 95% CI 2.3-45.5, p<0.01). In addition, 75% of those with aggressive lymphoma compared to 41% of patients with indolent lymphoma had fertility discussion (OR 4.2, 95% CI 1.5-12.4, p=0.01). White patients were significantly less likely than Hispanic, Black and Asian patients to have fertility discussion (OR 0.2, 95% CI 0.04-0.6, p<0.01).
In the multivariable analysis, alkylating therapy (OR 8.9, 95% CI 1.6-66.7) and age 18-39 years (OR 10.9, 95% CI 2.9-55.3) remained significant predictors of fertility discussion; White race was also trending towards significance (OR 0.2, 95% CI 0.04-1.0, p=0.08). Aggressive lymphoma subtype was not a significant predictor of fertility discussion.
Conclusions: In this cohort of lymphoma survivors 3 years post-diagnosis, we found that Hispanic patients, those diagnosed at a younger age and exposed to alkylating chemotherapy agents were significantly more likely to undergo discussions regarding the effects of lymphoma treatment on fertility. Our study highlights the importance of all cancer patients of childbearing age having the opportunity to address fertility concerns during clinic visits.
Casulo:Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Gilead Sciences, Secura Bio: Research Funding; AbbVie: Consultancy, Honoraria; Genmab: Research Funding; Verastem: Research Funding. Ahmed:Nektar: Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Research Funding; Bristol Myers Squibb: Research Funding; Merck: Research Funding; Xencor: Research Funding; Myeloid Therapeutics: Consultancy; ADC Therapeutics: Consultancy. Maurer:BMS: Consultancy, Research Funding; Roche/Genentech: Research Funding; GenMab: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Feldman:Seattle Genetics: Research Funding; Zeno Pharmaceuticals: Patents & Royalties. Link:Genentech: Research Funding. Cohen:Astra Zeneca: Consultancy, Research Funding; Lilly: Consultancy, Research Funding; Hutchmed: Consultancy, Research Funding; Janssen: Consultancy; Nurix: Research Funding; Kite/Gilead: Consultancy; Takeda: Research Funding; Genentech: Research Funding; Beigene: Consultancy. Habermann:Lilly: Other: Data Monitoring Committee. Chihara:MorPhosys: Research Funding; Genmab: Research Funding; Ono pharmaceutical: Research Funding; BeiGene: Honoraria; SymBio pharmaceutical: Honoraria; BMS: Research Funding. Lossos:Not specified: Patents & Royalties; University of Miami: Current Employment; ADCT: Research Funding. Kahl:AstraZeneca, BeiGene, Roche: Research Funding; BMS, BeiGene, Lilly, Kite, AZ, AbbVie, Merck, Novartis, Genentech, Roche, ADCT: Consultancy. Martin:AbbVie, AstraZeneca, Beigene, Daiichi Sankyo, Genentech, Janssen, Merck, Pepromene: Consultancy. Flowers:Burroughs Wellcome Fund: Research Funding; Cellectis: Research Funding; EMD Serono: Research Funding; Celgene: Consultancy, Research Funding; 4D: Research Funding; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research: Research Funding; Adaptimmune: Research Funding; Gilead: Consultancy, Research Funding; Janssen Pharmaceuticals: Research Funding; Foresight Diagnostics: Consultancy, Current holder of stock options in a privately-held company; Pharmacyclics: Research Funding; Xencor: Research Funding; Eastern Cooperative Oncology Group: Research Funding; N-Power Medicine: Consultancy, Current holder of stock options in a privately-held company; Spectrum: Consultancy; Acerta: Research Funding; Kite: Research Funding; Allogene: Research Funding; Iovance: Research Funding; Denovo Biopharma: Consultancy; TG Therapeutics: Research Funding; Bristol Myers Squibb: Consultancy; Pfizer: Research Funding; Sanofi: Research Funding; Takeda: Research Funding; Seagen: Consultancy; Pharmacyclics / Janssen: Consultancy; Guardant: Research Funding; Amgen: Research Funding; Ziopharm National Cancer Institute: Research Funding; Nektar: Research Funding; Novartis: Research Funding; Morphosys: Research Funding; AbbVie: Consultancy, Research Funding; BostonGene: Research Funding; BeiGene: Consultancy; Bayer: Consultancy, Research Funding; Karyopharm: Consultancy; Genmab: Consultancy; Genentech/Roche: Consultancy, Research Funding; AstraZeneca: Consultancy; Bio Ascend: Consultancy. Cerhan:Genentech: Research Funding; GenMab: Research Funding; BMS: Research Funding; Protagonist Therapeutics: Other: SMC. Rosenthal:RMEI, Curio Science, Targeted Oncology, OncLiveU: Other: Educational Workshop Speaker Role.